Association of plasma and cortical amyloid beta is modulated by APOE ε4 status

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Alzheimer's & Dementia

• Publication date

  2014-01-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.jalz.2013.01.007PMID 23541187PMCID PMC3750076
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• R: A language and environment for statistical computing.

  2014cited by this paper
• 2013 Alzheimer's disease facts and figures

  2013cited by this paper
• Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis.

  2012cited by this paper
• A Multifaceted Role for apoE in the Clearance of Beta-Amyloid across the Blood-Brain Barrier

  2012cited by this paper
• P1‐071: Intensity of dementia through latent variable modelling (I‐DeLV) in the AIBL cohort

  2012cited by this paper
• Correlation of Amyloid PET Ligand Florbetapir F 18 Binding With A&bgr; Aggregation and Neuritic Plaque Deposition in Postmortem Brain Tissue

  2012cited by this paper
• Improved protocol for measurement of plasma β‐amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients

  2012cited by this paper
• Stimulation of the Retinoid X Receptor Facilitates Beta-Amyloid Clearance Across the Blood–Brain Barrier

  2012cited by this paper
• Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.

  2012cited by this paper
• The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• Apolipoprotein E: Isoform Specific Differences in Tertiary Structure and Interaction with Amyloid-β in Human Alzheimer Brain

  2011influential reference
• Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI

  2011cited by this paper
• Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance

  2011cited by this paper
• Amyloid pathway-based candidate gene analysis of [11C]PiB-PET in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort

  2011cited by this paper
• Use of florbetapir-PET for imaging beta-amyloid pathology.

  2011cited by this paper
• Cerebrospinal fluid profiles and prospective course and outcome in patients with amnestic mild cognitive impairment.

  2011cited by this paper
• Plasma Aβ and PET PiB binding are inversely related in mild cognitive impairment

  2011cited by this paper
• The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• C-terminal-truncated apolipoprotein (apo) E4 inefficiently clears amyloid-β (Aβ) and acts in concert with Aβ to elicit neuronal and behavioral deficits in mice

  2011cited by this paper
• Meta-Analysis of Plasma Amyloid-β levels in Alzheimer's Disease

  2011cited by this paper
• Blood-based biomarkers for Alzheimer's disease: plasma Aβ40 and Aβ42, and genetic variants.

  2011cited by this paper
• Apolipoprotein E Regulates the Integrity of Tight Junctions in an Isoform-dependent Manner in an in Vitro Blood-Brain Barrier Model*

  2011cited by this paper
• The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans

  2010cited by this paper
• In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18)

  2010cited by this paper
• Blood-based biomarkers of Alzheimer's disease: challenging but feasible.

  2010cited by this paper
• APOE Genotype Results in Differential Effects on the Peripheral Clearance of Amyloid-β42 in APOE Knock-in and Knock-out Mice

  2010cited by this paper
• The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core

  2010cited by this paper
• Plasma Amyloid-β as a Biomarker in Alzheimer's Disease: The AIBL Study of Aging

  2010cited by this paper
• Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans

  2010cited by this paper
• Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

  2010cited by this paper
• Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease

  2009cited by this paper
• Baseline MRI Predictors of Conversion from MCI to Probable AD in the ADNI Cohort

  2009cited by this paper
• Amyloid Imaging in Aging and Dementia: Testing the Amyloid Hypothesis In Vivo

  2009cited by this paper
• Relationships between biomarkers in aging and dementia

  2009cited by this paper
• Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

  2009cited by this paper
• Apolipoprotein E, Amyloid-&bgr;, and Blood-Brain Barrier Permeability in Alzheimer Disease

  2008cited by this paper
• The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods

  2008cited by this paper
• 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.

  2008cited by this paper
• 11 C PiB and structural MRI provide complementary information in imaging of Alzheimer ’ s disease and amnestic mild cognitive impairment

  2008cited by this paper
• Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans

  2006cited by this paper
• Faculty Opinions recommendation of Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

  2006cited by this paper
• Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

  2004cited by this paper
• Automated Talairach Atlas labels for functional brain mapping

  2000cited by this paper
• Mild Cognitive Impairment Clinical Characterization and Outcome

  1999cited by this paper
• Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis

  1997cited by this paper
• Automated labeling of the human brain: A preliminary report on the development and evaluation of a forward‐transform method

  1997cited by this paper
• Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.

  1997cited by this paper
• Statistical parametric maps in functional imaging: A general linear approach

  1994cited by this paper
• Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease.

  1993cited by this paper
• Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.

  1993cited by this paper
• Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease.

  1993cited by this paper
• Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease.

  1993cited by this paper
• Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

  1993cited by this paper
• Alzheimer ’ s disease facts and figures Alzheimer ’ s Association

  year unknowncited by this paper

• Combination of Aβ40, Aβ42, and Tau Plasma Levels to Distinguish Amyloid-PET Positive Alzheimer Patients from Normal Controls

  2025cites this paper
• Associations among plasma, MRI, and amyloid PET biomarkers of Alzheimer's disease and related dementias and the impact of health‐related comorbidities in a community‐dwelling cohort

  2024cites this paper
• Profiling of plasma biomarkers in the context of memory assessment in a tertiary memory clinic

  2023cites this paper
• Potential Biomarkers for Early Diagnosis of Alzheimer’s Disease and Primary Open-Angle Glaucoma

  2023cites this paper
• [Modern possibilities of early diagnosis of Alzheimer's disease in patients with primary open-angle glaucoma].

  2023cites this paper
• Vascular Risk Predicts Plasma Amyloid β 42/40 Through Cerebral Amyloid Burden in Apolipoprotein E ε4 Carriers

  2023cites this paper
• Prospective analysis of plasma amyloid beta and postoperative delirium in the Interventions for Postoperative Delirium: Biomarker-3 study.

  2023cites this paper
• [Potential biomarkers of early diagnosis of Alzheimer's disease].

  2022cites this paper
• Development of Alzheimer’s Disease Biomarkers: From CSF- to Blood-Based Biomarkers

  2022cites this paper
• Associations between physical activity, blood-based biomarkers of neurodegeneration, and cognition in healthy older adults: The MAPT study.

  2021cites this paper
• Blood‐based biomarkers for Alzheimer's disease

  2021cites this paper
• Blood Pressure Level Is Associated With Changes in Plasma Aβ1 –40 and Aβ1–42 Levels: A Cross-sectional Study Conducted in the Suburbs of Xi’an, China

  2021cites this paper
• Biomarkers and Tools for Predicting Alzheimer’s Disease in the Preclinical Stage

  2021cites this paper
• Total Aβ42/Aβ40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis

  2020cites this paper
• Immunity and amyloid beta, total tau and neurofilament light chain: Findings from a community‐based cohort study

  2020cites this paper
• Quantitative Measurement of Cerebrospinal Fluid Amyloid-β Species by Mass Spectrometry

  2020cites this paper
• Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases

  2019cites this paper
• Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study

  2019cites this paper
• Relationship of amyloid-β1–42 in blood and brain amyloid: Ginkgo Evaluation of Memory Study

  2019cites this paper
• Amyloid-β as a Blood Biomarker for Alzheimer’s Disease: A Review of Recent Literature

  2019cites this paper
• Circulating APP, NCAM and Aβ serve as biomarkers for Alzheimer's disease.

  2018cites this paper
• High performance plasma amyloid-β biomarkers for Alzheimer’s disease

  2018cites this paper
• The Relation Between Brain Amyloid Deposition, Cortical Atrophy, and Plasma Biomarkers in Amnesic Mild Cognitive Impairment and Alzheimer’s Disease

  2018cites this paper
• The Level of Plasma Amyloid-β40 Is Correlated with Peripheral Transport Proteins in Cognitively Normal Adults: A Population-Based Cross-Sectional Study

  2018cites this paper
• Aging and APOE‐ε4 are determinative factors of plasma Aβ42 levels

  2018cites this paper
• Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI)

  2018cites this paper
• The AIBL study group AIBL Biomarker Stream

  2018cites this paper
• Whole exome sequence-based association analyses of plasma amyloid-β in African and European Americans; the Atherosclerosis Risk in Communities-Neurocognitive Study

  2017cites this paper
• Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry

  2017cites this paper
• Blood Based Biomarkers in Alzheimer Disease: Current State of the Science and a Novel Collaborative Paradigm for Moving from Discovery to Clinic

  2017cites this paper
• State of Play in Alzheimer’s Disease Genetics

  2017cites this paper
• Blood‐based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic

  2017cites this paper
• Effect of apolipoprotein E phenotype on the association of plasma amyloid β and amyloid positron emission tomography imaging in Japan

  2017influential citation
• Quantitative multimodal multiparametric imaging in Alzheimer’s disease

  2016cites this paper
• Plasma β-amyloid in Alzheimer’s disease and vascular disease

  2016cites this paper
• Genetic risk factor APOEε4 associates with plasma amyloid beta in amnestic mild cognitive impairment and Alzheimer's disease.

  2016cites this paper
• Modifications of the endosomal compartment in peripheral blood mononuclear cells and fibroblasts from Alzheimer's disease patients

  2015cites this paper
• The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans

  2015cites this paper
• Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans

  2015cites this paper
• Plasma amyloid β-quo vadis?

  2015cites this paper
• Plasma amyloid‐β and risk of Alzheimer's disease in the Framingham Heart Study

  2015cites this paper
• The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.

  2014cites this paper
• Genetic Heterogeneity in Alzheimer Disease and Implications for Treatment Strategies

  2014cites this paper